Mayne Pharma Group Ltd.ASX: MYX

Mayne Pharma market update

· Issued by Mayne Pharma Group Ltd.

Filed with ASX · · 2 pages · English

Summary by 6ix AI

Mayne Pharma Group Ltd. has released a market update for the first half of the fiscal year, detailing expected revenue and EBITDA growth compared to the previous year. This growth is attributed to strong performance in the Women’s Health portfolio and improved margins in Dermatology. The preliminary results are pending final auditor review and board approval, with full details to be disclosed later this month.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Mayne Pharma Group Ltd. on 6ix

Earlier from Mayne Pharma

Later from Mayne Pharma

All Mayne Pharma news releases